Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.
暂无分享,去创建一个
W. Hiddemann | R. Buhmann | M. Hallek | L. Perabò | D. Kofler | H. Büning | C. Wendtner | J. Baumert | C. Schweighofer | C. Kurzeder | H. Theiss | S. Danhauser‐Riedl
[1] D. McCarty,et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.
[2] M. Hallek,et al. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors , 2001, Gene Therapy.
[3] M Chilosi,et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[4] R. Samulski,et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] L. Rassenti,et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.
[6] J. Gribben,et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies , 2000, Nature Medicine.
[7] K. Anderson,et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. , 2000, Blood.
[8] Jody A. Vandergriff,et al. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.
[9] Arun Srivastava,et al. Impaired Intracellular Trafficking of Adeno-Associated Virus Type 2 Vectors Limits Efficient Transduction of Murine Fibroblasts , 2000, Journal of Virology.
[10] J. Qiu,et al. Integrin αVβ5 Is Not Involved in Adeno-Associated Virus Type 2 (AAV2) Infection , 1999 .
[11] Y. Hanazono,et al. In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. , 1999, Blood.
[12] G. Deléage,et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.
[13] P. Dijkhuizen,et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. , 1999, Human gene therapy.
[14] W. Hahn,et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.
[15] B. Byrne,et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.
[16] R. Buhmann,et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. , 1999, Blood.
[17] J. Qiu,et al. Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection. , 1999, Virology.
[18] Keyun Qing,et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.
[19] R. Samulski,et al. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.
[20] G. Deléage,et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.
[21] D. Grimm,et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.
[22] Arun Srivastava,et al. Adeno-Associated Virus Type 2-Mediated Gene Transfer: Role of Epidermal Growth Factor Receptor Protein Tyrosine Kinase in Transgene Expression , 1998, Journal of Virology.
[23] D. Schadendorf,et al. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. , 1998, Human gene therapy.
[24] T. Kipps,et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.
[25] R. Samulski,et al. Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.
[26] S. Ponnazhagan,et al. Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo , 1998, Journal of Virology.
[27] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[28] T. Kipps,et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.
[29] R. Buhmann,et al. Gene transfer of costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response , 1997, Gene Therapy.
[30] S. Ponnazhagan,et al. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Kipps,et al. Adenovirus vector infection of chronic lymphocytic leukemia B cells. , 1996, Blood.
[32] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[33] R. Kotin,et al. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. , 1995, Human gene therapy.
[34] D. Russell,et al. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] D. Russell,et al. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors , 1994, Journal of virology.
[36] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] T. Kipps,et al. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.
[38] A. Lanzavecchia,et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation , 1993, The Journal of experimental medicine.
[39] Samulski,et al. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression , 1989, Journal of virology.
[40] R. Samulski,et al. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication , 1987, Journal of virology.